DETAILS, FICTION AND Z-LEHD-FMK

MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage numerous intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial aims had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyo